Skip to main content

Drug Interactions between capivasertib and pralsetinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pralsetinib capivasertib

Applies to: pralsetinib and capivasertib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme. A physiologically based pharmacokinetic (PBPK) model predicted pralsetinib's peak plasma concentration (Cmax) and systemic exposure (AUC) would increase by 1.2- and 2.2-fold, respectively, when coadministered with the potent CYP450 3A4 inhibitor voriconazole (400 mg twice daily on Day 1, followed by 200 mg twice daily). Similarly, another PBPK model predicted that concomitant use of the moderate CYP450 3A4 inhibitor fluconazole (400 mg daily) would increase the Cmax and AUC of pralsetinib by 1.2- and 1.7-fold, respectively. The extent to which other, less potent CYP450 3A4 inhibitors may interact with pralsetinib is unknown. Increased exposure to pralsetinib may increase the risk and/or frequency of adverse effects such as interstitial lung disease/pneumonitis, liver transaminase elevations, hypertension, and hemorrhage. Some clinical trials have also observed prolongation of the QT interval in patients on pralsetinib, though this was not observed in a study of 34 patients with rearranged during transfection (RET)-altered solid tumors on pralsetinib at the recommended dosage.

MANAGEMENT: Caution is advised when pralsetinib is used with CYP450 3A4 inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.

Drug and food interactions

Major

pralsetinib food

Applies to: pralsetinib

Food should not be consumed for at least 2 hours before and at least 1 hour after taking pralsetinib. Do not consume grapefruit, grapefruit juice, any supplements that contain grapefruit, Seville oranges, or Seville orange juice as these products can increase the blood levels of pralsetinib. This may increase the risk and/or severity of serious side effects such as lung problems, liver problems, high blood pressure, fatigue, muscle and joint pain, and bleeding complications. Some sources also warn that combining these medicines could increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac disease, conduction abnormalities, or electrolyte disturbance (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major

capivasertib food

Applies to: capivasertib

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with capivasertib as they may increase the blood levels of capivasertib. This may increase the risk of side effects such as high blood sugar levels, diarrhea, skin reactions, nausea, vomiting, tiredness, and changes in certain blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • capivasertib
  • pralsetinib

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer